Unexpected benefits of allergies and cigarette smoking: Two examples of paradox in neuroepidemiology

The Paradoxical Brain

Volumn , Issue , 2011, Pages 261-273

  Schwartzbaum, Judith ^a   Karavodin, Linda ^b   Kapur, Narinder ^c,d,e   Fisher, James L ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b Karavodin Preclinical Consulting   (United States)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^e ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84931834391     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1017/CBO9780511978098.016     Document Type: Chapter

References (90)

1. Akdis, C. A., Joss, A., Akdis, M., & Blaser, K. (2001). Mechanism of IL-10-induced T cell inactivation in allergic inflammation and normal response to allergens. International Archives of Allergy and Immunology, 124: 180-2.
2. Allam, M. F., Campbell, M. J., Del Castillo, A. S., & Fernandez-Crehuet Navajas, R. (2004b). Parkinson's disease protects against smoking? Behavioural Neurology, 15: 65-71.
3. Allam, M. F., Campbell, M. J., Hofman, A., Del Castillo, A. S., & Fernandez-Crehuet Navajas, R. (2004a). Smoking and Parkinson's disease: systematic review of prospective studies. Movement Disorders: Official Journal of The Movement Disorder Society, 19: 614-21.
4. Baek, K., Zaslavsky, A., Lynch, R. C., et al. (2009). Down's syndrome suppression of tumor growth and the role of calcineurin inhibitor DSCR1. Nature, 459: 1126-30.
5. Bahmanyar, S, Montgomery, S. M., Hillert, J., Ekbom, A., & Olsson, T. (2009). Cancer risk among patients with multiple sclerosis and their parents Neurology, 72: 1170-7.
6. Barak, Y., Achiron, A., Mandel, A., Mirecki, I., & Aizenberg, D. (2005). Reduced cancer incidence among patients with schizophrenia. Cancer, 104: 2817-21.
7. Barna, B. P., Estes, M. L., Pettay, J., Iwasaki, K., Zhou, P., & Barnett, G. H. (1995). Human astrocyte growth regulation: interleukin-4 sensitivity and receptor expression. Journal of Neuroimmunology, 60: 75-81.
8. Benedetti, M. D., Bower, J. H., Maraganore, D. M., et al. (2000). Smoking, alcohol, and coffee consumption preceding Parkinson's disease: a case-control study. Neurology, 55: 1350-8.
9. Burnet, N., Jeffries, S., Benson, R., Hunt, D., & Treasure, F. (2005). Years of life lost (YLL) from cancer is an important measure of population burden-and should be considered when allocating research funds. British Journal of Cancer, 92: 241-5.
10. Castagnoli, K., & Murugesan, T. (2004). Tobacco leaf, smoke and smoking, MAO inhibitors, Parkinson's disease and neuroprotection; are there links? Neurotoxicology, 25: 279-91.
11. Checkoway, H., Powers, K., Smith-Weller, T., Franklin, G. M., Longstreth, W.T., Jr., & Swanson, P. D. (2002). Parkinson's disease risks associated with cigarette smoking, alcohol consumption, and caffeine intake. American Journal of Epidemiology, 155: 732-8.
12. Debanne, S. M., Bielefeld, R. A., Cheruvu, V. K., Fritsch, T., & Rowland, D. Y. (2007). Alzheimer's disease and smoking: bias in cohort studies. Journal of Alzheimer's Disease, 11: 313-21.
13. Deleu, D. (2001). Smoking, alcohol, and coffee consumption preceding Parkinson's disease. Neurology, 56: 984-5.
14. Dinarello, C. A. (2003). Setting the cytokine trap for autoimmunity. Nature Medicine, 9: 20-2.
15. Dong, J. Q., Zhang, Z. X., & Zhang, K. L. (2003). Parkinson's disease and smoking: an integral part of PD's etiological study. Biomedical and Environmental Sciences, 16: 173-9.
16. Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J., & Schreiber, R. D. (2002). Cancer immunoediting: from immunosurveillance to tumor escape. Nature Immunology, 3: 991-8.
17. Evans, A. H., Lawrence, A. D., Potts, J., et al. (2006). Relationship between impulsive sensation seeking traits, smoking, alcohol and caffeine intake, and Parkinson's disease. Journal of Neurology, Neurosurgery, and Psychiatry, 77: 317-21.
18. Eysenck, H. J. (1991). Were we really wrong? American Journal of Epidemiology, 133: 429-33.
19. Eysenck, H. J. (1995). Does smoking really kill anybody? Psychological Reports, 77: 1243-6.
20. Fonarow, G. C., Abraham, W. T., Albert, N. M., et al. (2008). A smoker's paradox in patients hospitalized for heart failure: findings from OPTIMIZE-HF. European Heart Journal, 29: 1983-91.
21. Fowler, J. S., Volkow, N. D., Wang, G. J., et al. (1996). Inhibition of monoamine oxidase B in the brains of smokers. Nature, 379: 733-6.
22. Fowler, J. S., Wang, G., Volkow, N. D., et al. (2000). Maintenance of brain monoamine oxidase B inhibition in smokers after overnight cigarette abstinence. American Journal of Psychiatry, 157: 1864-6.
23. Fox, B. H., & Howell, M. A. (1974). Cancer risk among psychiatric patients: a hypothesis. International Journal of Epidemiology, 3: 207-08.
24. Fratiglioni, L., & Wang, H. X. (2000). Smoking and Parkinson's and Alzheimer's disease: review of the epidemiological studies. Behavioural Brain Research, 113: 117-20.
25. Fulcher, T., Griffin, M., Crowley, S., Firth, R., Acheson, R., & O’Meara, N. (1998). Diabetic retinopathy in Down's syndrome. British Journal of Ophthalmology, 82: 407-09.
26. Galanaud, J. P., Elbaz, A., Clavel, J., et al. (2005). Cigarette smoking and Parkinson's disease: a case-control study in a population characterized by a high prevalence of pesticide exposure. Movement Disorders: Official Journal of the Movement Disorder Society, 20: 181-9.
27. Gomez, G. G., & Kruse, C. A. (2006). Mechanisms of malignant glioma immune resistance and sources of immunosuppression. Gene Therapy and Molecular Biology, 10: 133-46.
28. Hancock, D. B., Martin, E. R., & Stajich, J. M., (2007). Smoking, caffeine, and nonsteroidal anti-inflammatory drugs in families with Parkinson disease. Archives of Neurology, 64: 576-80.
29. Hasle, H., Clemmensen, I. H., & Mikkelsen, M. (2000). Risks of leukaemia and solid tumors in individuals with Down's syndrome. Lancet, 355: 165-9.
30. Hausenloy, D. J., Mwamure, P. K., Venugopal, V., et al. (2007). Effect of remote ischaemic preconditioning on myocardial injury in patients undergoing coronary artery bypass graft surgery: a randomised controlled trial. Lancet, 370: 575-9.
31. Helzner, E. P., Luchsinger, J. A., Scarmeas, N., et al. (2009). Contribution of vascular risk factors to the progression in Alzheimer disease. Archives of Neurology, 66: 343-8.
32. Hernan, M. A., Takkouche, B., Caamao-Isorna, F., & Gestal-Otero, J. J. (2002). A metaanalysis of coffee drinking, cigarette smoking, and the risk of Parkinson's disease. Annals of Neurology, 52: 276-84.
33. Hernan, M. A., Zhang, S. M., Rueda-deCastro, A. M., Colditz, G. A., Speizer, F. E., & Ascherio, A. (2001). Cigarette smoking and the incidence of Parkinson's disease in two prospective studies. Annals of Neurology, 50: 780-6.
34. Hoffman, S., Propp, J. M., & McCarthy, B. J. (2005). Temporal trends in incidence of primary brain tumors in the United States, 1985-1999. Neuro-Oncology [serial online], Doc. 05-032.
35. Hong, D. P., Fink, A. L., & Uversky, V. N. (2009). Smoking and Parkinson's disease: does nicotine affect alpha-synuclein fibrillation? Biochimica et Biophysica Acta, 1794: 282-90.
36. James, W. H. (2003). Coffee drinking, cigarette smoking, and Parkinson's disease. Annals of Neurology, 53: reply 546.
37. Jordan, J. T., Sun, W., Hussain, S. F., DeAngulo, G., Prabhu, S. S., & Heimberger, A. B. (2008). Preferential migration of regulatory T cells mediated by glioma-secreted chemokines can be blocked with chemotherapy. Cancer, Immunology and Immunotherapy, 57: 123-31.
38. Kandinov, B., Giladi, N., & Korczyn, A. D. (2007). The effect of cigarette smoking, tea, and coffee consumption on the progression of Parkinson's disease. Parkinsonism & Related Disorders, 13: 243-5.
39. Kandinov, B., Giladi, N., & Korczyn, A. D. (2009). Smoking and tea consumption delay onset of Parkinson's disease. Parkinsonism & Related Disorders, 15: 41-6.
40. Katayama, T., Iwasaki, Y., Sakoda, N., & Yoshioka, M. (2008). The etiology of ‘smoker's paradox’ in acute myocardial infarction with special emphasis on the association with inflammation. International Heart Journal, 49: 13-24.
41. Kelada, S. N., Costa-Mallen, P., Costa, L. G., et al. (2002). Gender difference in the interaction of smoking and monoamine oxidase B intron 13 genotype in Parkinson's disease. Neurotoxicology, 23: 515-9.
42. Kievit, P. C., Brouwer, M. A., Veen, G., Aengevaeren, W. R., & Verheugt, F. W. (2009). The smoker's paradox after successful fibrinolysis: reduced risk of reocclusion but no improved long-term cardiac outcome. Journal of Thrombosis and Thrombolysis, 27: 385-93.
43. Krone, B., Oeffner, F., & Grange, J. M. (2009). Is the risk of multiple sclerosis related to the biography of the immune system? Journal of Neurology, 256: 1052-60.
44. Linos, E., Raine, T., Alonso, A., & Michaud, D. (2007). Atopy and risk of brain tumors: a meta-analysis. Journal of the National Cancer Institute, 99: 1544-50.
45. Liu, H., Jacobs, B. S., Liu, J., et al. (2000b). Interleukin-13 sensitivity and receptor phenotypes of human glial cell lines: nonneoplastic glia and low-grade astrocytoma differ from malignant glioma. Cancer, Immunology and Immunotherapy, 49: 19-24.
46. Liu, H., Prayson, R. A., Estes, M. L., et al. (2000a). In vivo expression of the interleukin 4 receptor alpha by astrocytes in epilepsy cerebral cortex. Cytokine, 12: 1656-61.
47. Louis, D. N. (1997). A molecular genetic model of astrocytoma histopathology. Brain Pathology, 7: 755-64.
48. Marder, K., & Logroscino, G. (2002). The everstimulating association of smoking and coffee and Parkinson's disease. Annals of Neurology, 52: 261-2.
49. McGeer, P., Schultzer, M., & McGerr, E. G. (1996). Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies. Neurology, 47: 425-32.
50. Melbye, M., Smedby, K. E., Lehtinen, T., et al. (2007). Atopy and risk of non-Hodgkin lymphoma. Journal of the National Cancer Institute, 99: 158-66.
51. Mielke, M. M., Rosenberg, P. B., Tschanz, J., et al. (2007). Vascular factors predict rate of progression in Alzheimer disease. Neurology, 69: 1850-8.
52. Mitchell, S., Elkind, V., Ramakrishnan, P., et al. (2009). Infectious burden and risk of stroke: the Northern Manhattan Study. Archives of Neurology, 67: doi:10.1001/achneurol.2009.271.
53. Moncayo, J., de Freitas, G. R., Bogousslavsky, J., Altieri, M., & van Melle, G. (2000). Do transient ischemic attacks have a neuroprotective effect? Neurology, 54: 2089-94.
54. Morozova, N., O’Reilly, E. J., & Ascherio, A. (2008). Variations in gender ratios support the connection between smoking and Parkinson's disease. Movement Disorders: Official Journal of the Movement Disorder Society, 23: 1414-9.
55. Murdoch, J. C., Rodger, J. C., Rao, S. S., Fletcher, C. D., & Dunnigan, M. G. (1977). Down's Syndrome: an atheroma-free model? British Medical Journal, 2: 226-8.
56. Nielsen, N. M., Rostgaard, K., Rasmussen, S., et al. (2006). Cancer risk among patients with multiple sclerosis: a population-based register study. International Journal of Cancer, 118: 979-84.
57. Norhashemi, F. (1999). Low Alzheimer's disease prevalence in rheumatoid arthritis patients is unrelated to ApoE genotype. European Journal of Internal Medicine, 10: 97-100.
58. O’Duffy, A. E., Bordelon, Y. M., & McLaughlin, B. (2007). Killer proteases and little strokes-how the things that do not kill you make you stronger. Journal of Cerebral Blood Flow and Metabolism, 27: 665-8.
59. Park, J. K., Lee, H. J., Kim, J. W., et al. (2004). Differences in p53 gene polymorphisms between Korean schizophrenia and lung cancer patients. Schizophrenia Research, 67: 71-4.
60. Patja, K., Pukkala, E., Sund, R., Iivanainen, M., & Kaski, M. (2006). Cancer incidence of persons with Down syndrome in Finland: a population-based study. International Journal of Cancer, 118: 1769-72.
61. Powers, K. M., Kay, D. M., Factor, S. A., et al. (2008). Combined effects of smoking, coffee, and NSAIDs on Parkinson's disease risk. Movement Disorders: Official Journal of the Movement Disorder Society, 23: 88-95.
62. Regan, C., Katona, C., Walker, Z., Hooper, J., Donovan, J., & Livingston, G. (2006). Relationship of vascular risk to the progression of Alzheimer disease. Neurology, 67: 1357-62.
63. Ritz, B., Ascherio, A., Checkoway, H., et al. (2007). Pooled analysis of tobacco use and risk of Parkinson disease. Archives of Neurology, 64: 990-7.
64. Sanz, C., Andrieu, S., Sinclair, A., Hanaire, H., & Vellas, B. (2009). Diabetes is associated with a slower rate of cognitive decline in Alzheimer disease. Neurology, 73: 1359-66.
65. Satge, D., Sasco, A. J, Carlsen, N. L., et al. (1998). A lack of neuroblastoma in Down syndrome: a study from 11European countries. Cancer Research, 58: 448-52.
66. Scheurer, M. E., El-Zein, R., Thompson, P. A., et al. (2008). Long-term anti-inflammatory and antihistamine medication use and adult glioma risk. Cancer Epidemiology: Biomarkers and Prevention, 17: 1277-81.
67. Schwartzbaum, J., Ahlbom, A., Malmer, B., et al. (2005). Polymorphisms associated with asthma are inversely related to glioblastoma multiforme. Cancer Research, 65: 6459-65.
68. Schwartzbaum, J., Xiao, Y., Liu, Y., et al. (2010b) Inherited variation in immune genes and pathways and glioblastoma risk. Carcinogenesis. Epub 2010b Aug 1.
69. Schwartzbaum, J. A., Ahlbom, A., Lonn, S., et al. (2007). An international case-control study of glutathione transferase and functionally related polymorphisms and risk of primary adult brain tumors. Cancer Epidemiology: Biomarkers and Prevention, 16: 559-65.
70. Schwartzbaum, J. A., Huang, K., Lawler, S., Ding, B., Yu, J., & Chiocca, E. A. (2010a). Allergy and inflammatory transcriptome is predominantly negatively correlated with CD133 expression in glioblastoma. Neuro-Oncology, 12: 320-7.
71. Scott, W. K., Zhang, F., Stajich, J. M., Scott, B. L., Stacy, M. A., & Vance, J. M. (2005). Family-based case-control study of cigarette smoking and Parkinson disease. Neurology, 64: 442-7.
72. Soderberg, K. C., Jonsson, F., Winqvist, O., Hagmar, L., & Feychting, M. (2006). Autoimmune diseases, asthma and risk of haematological malignancies: a nationwide case-control study in Sweden. European Journal of Cancer, 42: 3028-33.
73. Surgeon General's Report. (2004). The health consequences of smoking: a report of the Surgeon General. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, Washington, DC. For sale by the Supt. of Docs., U.S. G.P.O.
74. Tan, E. K., Chai, A., Lum, S. Y., et al. (2003b). Monoamine oxidase B polymorphism, cigarette smoking and risk of Parkinson's disease: a study in an Asian population. American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics: The Official Publication of the International Society of Psychiatric Genetics, 120B: 58-62.
75. Tan, E. K., Tan, C., Fook-Chong, S. M., et al. (2003a). Dose-dependent protective effect of coffee, tea, and smoking in Parkinson's disease: a study in ethnic Chinese. Journal of the Neurological Sciences, 216: 163-7.
76. Tanner, C. M., Goldman, S. M., Aston, D. A., et al. (2002). Smoking and Parkinson's disease in twins. Neurology, 58: 581-8.
77. Terabe, M., Khanna, C., Bose, S., Melchionda, F., Mendoza, A., Mackall, C. L., et al. (2006). CD1d-restricted natural killer T cells can down-regulate tumor immunosurveillance independent of interleukin-4 receptor-signal transducer and activator of transcription 6 or transforming growth factor-beta. Cancer Research, 66: 3869-75.
78. Thacker, E. L., O’Reilly, E. J., Weisskopf, M. G., et al. (2007). Temporal relationship between cigarette smoking and risk of Parkinson disease. Neurology 68: 764-8.
79. Umetsu, D. T., & DeKruyff, R. H. (2006). The regulation of allergy and asthma. Immunology Review, 212: 238-55.
80. Wegener, S., Gottschalk, B., Jovanovic, V., et al. (2004). Transient ischemic attacks before ischemic stroke: preconditioning the human brain? A multicenter magnetic resonance imaging study. Stroke, 35: 616-21.
81. Weisskopf, M. G., Grodstein, F., & Ascherio, A. (2007). Smoking and cognitive function in Parkinson's disease. Movement Disorders: Official Journal of the Movement Disorder Society, 22: 660-5.
82. Wiemels, J. L., Wiencke, J. K., Patoka, J., et al. (2004). Reduced immunoglobulin E and allergy among adults with glioma compared with controls. Cancer Research, 64: 8468-73.
83. Wiemels, J. L., Wilson, D., Patil, C., et al. (2009). IgE, allergy, and risk of glioma: update from the San Francisco Bay Area Adult Glioma Study in the Temozolomide era. International Journal of Cancer, 125: 680-7.
84. Wigertz, A. (2008). Factors associated with brain tumor risk: with focus on female sex hormones and allergic conditions. Dissertation, Karolinska Institutet, Stockholm, Sweden.
85. Wrensch, M., Lee, M., Miike, R., et al. (1997). Familial and personal medical history of cancer and nervous system conditions among adults with glioma and controls. American Journal of Epidemiology, 145: 581-93.
86. Wrensch, M., Weinberg, A., Wiencke, J., Miike, R., Barger, G., & Kelsey, K. (2001). Prevalence of antibodies to four herpesviruses among adults with glioma and controls. American Journal of Epidemiology, 154: 161-5.
87. Wrensch, M., Weinberg, A., Wiencke, J., et al. (2005).History of chickenpox and shingles and prevalence of antibodies to varicella-zoster virus and three other herpesviruses among adults with glioma and controls. American Journal of Epidemiology, 161: 929-38.
88. Wrensch, M., Wiencke, J. K., Wiemels, J., et al. (2006). Serum IgE, tumor epidermal growth factor receptor expression, and inherited polymorphisms associated with glioma survival. Cancer Research, 66: 4531-41.
89. Yang, Q., Rasmussen, S. A., & Friedman, J. M. (2002). Mortality associated with Down's syndrome in the USA from 1983 to 1997: a population-based study. Lancet, 359: 1019-25.
90. Yang, Y., Xiao, Z., Chen, W., et al. (2004). Tumor suppressor gene TP53 is genetically associated with schizophrenia in the Chinese population. Neuroscience Letters, 369: 126-31.